Endothelial progenitor cells (EPCs) are applied in the treatment of ischemic diseases. In ex vivo culture of human cord-blood derived EPCs, H1152, (S)-(+)-2-methyl-1-[(4-methyl-5-iso-quinolinyl) sulfonyl]-homopiperazine, markedly increased the number of EPCs. It also induced EPC migration, stimulated the phosphorylation of AKT, and reduced the expression of p27 in the EPCs. Thus H1152 can be used effectively in ex vivo expansion of EPCs.
Accumulating evidence has demonstrated that the Rho/Rho kinase (ROCK) pathway plays an important role in various cellular functions that might be involved in the pathogenesis of cardiovascular diseases, including cerebral and coronary vasospasm, angina, hypertension, pulmonary hypertension, and heart failure. 1, 2) The Rho/ ROCK pathway has been found to be a powerful mediator of endothelial dysfunction in vitro. 3) In human endothelial cells, activation of ROCK results in reduced eNOS expression and activity, which are reversed by the addition of the ROCK inhibitor. 4 ) Pharmacological inhibition of ROCK shows effects consistent with the roles of RhoA signaling in the development of heart failure and responses to ischemic damage. 5) Endothelial progenitor cells (EPCs) are applied therapeutically to improve angiogenesis in ischemic disease. [6] [7] [8] The numbers, and migratory activity of circulating EPCs correlate inversely with the risk factors for coronary artery disease. 9, 10) The limited number of EPCs applied in clinical usage is the biggest obstacle to therapeutic use. Hence enhancement of EPC numbers is a useful way to treat ischemic disease. During screening of inhibitors to increase EPC numbers, we found that ROCK inhibitor Y27632 increased the number of spindle-shaped adherent cells in EPC culture (Fig. 1A) . Inhibition of Rho-dependent kinases ROCK1/2 by H1152 has been reported to activate vascular endothelial growth factor (VEGF)-driven retinal neovascularization. 11) In addition, H1152 is known to be a more potent ROCK inhibitor than Y27632 and fasudil. 12, 13) Hence we examined the effects of H1152 on EPC to explore the possibility of employing H1152 for EPC expansion. Human umbilical cord blood samples were collected by procedures approved by the Institutional Review Board of The Catholic University of Korea, College of Medicine (approval no. CUMC10U901). Our study conformed to the principles outlined in the Declaration of Helsinki for the use of human tissue and subjects. Mononuclear cells (MNCs) were isolated from cord blood using Ficoll-Paque premium (density 1.077; GE Healthcare, New York, NY) density gradient centrifugation methods, as previously described.
14) Isolated MNCs (2,500 cells/mm 2 ) were plated on culture dishes coated with 20 mg/mL of human fibronectin and maintained in 20% FBS (Gibco BRL, Grand Island, NY), 30 mg/mL of endothelial cell growth supplements (Sigma, St. Louis, MO), 90 mg/mL of heparin (Sigma), and 1% antibiotics in M199 (Gibco BRL). After 3 d of culture, nonadherent cells were removed by washing with PBS, and adherent cells were treated with H1152 (0.01-10 mM) for 2 d. To characterize the cells to have the features of cells in the endothelial lineage, we examined adherent cells for uptake of 1,1 0 -dioctadecyl-3,3,3 0 ,3 0 -tetramethylindocarbocyanine-labeled acetylated low-density lipoprotein (Dil-ac-LDL, Invitrogen, Eugene, OR) and for binding of Ulex europaeus agglutinin-I (UEA-1, Sigma) as described previously.
14) The nuclei were stained with Hoechst 33342 (Sigma). As shown in Fig. 1B , the number of adherent cells was increased by H1152 treatment, and the ratio of the number of cells positive for ac-LDL uptake and UEA-1 binding to the total number of adherent cells did not significantly change upon treatment (0-7% difference as compared to control). The number of EPCs, which were ac-LDL+/ UEA-1+, increased markedly from 539:80 AE 14:60 cells/mm 2 (untreated) to 809:92 AE 74:64 cells/mm 2 when H1152 was added at 0.1 mM. However, due to * These authors contributed equally to this study.
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Abbreviations: EPC, endothelial progenitor cell; DiI-acLDL, 1,1 0 -dioctadecyl-3,3,3 0 ,3 0 -tetramethylindocarbocyanine-labeled acetylated lowdensity lipoprotein; MNC, mononuclear cell; ROCK, Rho kinase; SDF-1, stromal cell-derived factor-1; UEA-1, Ulex europaeus agglutinin-1; VEGF, vascular endothelial growth factor the potency of H1152, no increase in EPC numbers was observed at 10 mM, at which fasudil showed a marked increase in cell numbers. Fasudil also reduced the increase in EPC numbers at a high concentration, 30 mM (data not shown). The ratio of spindle-shaped cells increased upon treatment with H1152 at low concentrations, like the cells treated with 10 mM of Y27632 (Fig. 1A) . However, at 10 mM of H1152, adherent cells of round shape prevailed with no increase in cell numbers. Hence it was concluded that H1152 efficiently increases EPC numbers at low concentrations under ex vivo culture conditions of EPCs. This corresponds well with a previous report that H1152 has a 206-or 87-fold lower Ki value for ROCK than fasudil or Y27632. 12) Next we examined whether H1152 induces EPC migration, since ROCK is involved in actin cytoskeleton rearrangement and thus affects cell motility. 15 ) ROCK inhibitors can inhibit or enhance cell migration and functions. [16] [17] [18] [19] Cell migration was evaluated using a 48-well modified Boyden Chamber (Neuro Probe, Cabin John, MD), as described previously. 20) EPCs cultured for 5 d were harvested and placed into upper chambers (2 Â 10 4 /well). Stromal cell-derived factor-1 (SDF-1), VEGF, H1152, or fasudil was added to the bottom chambers. After assembly of the chambers, the cells were allowed to migrate for 6 h. The migrating cells were fixed and stained with Diff-Quik Solution (Sysmex, Kobe, Japan). The stained cells were photographed and counted. Low doses, from 0.01 to 1 mM of H1152, significantly promoted EPC migration (Fig. 2) . In contrast to its effect on EPC numbers, 10 mM of H1152 increased EPC migration to the highest level. Since H1152 was added to the bottom chamber while the cells were placed in the upper chamber, the concentration required to promote EPC migration might be higher than the concentration to promote EPC numbers. A similar promoting effect on migration was observed for fasudil in a dose range from 1 to 10 mM. These results suggest that H1152 significantly promotes EPC migration, and correspond well with a previous report that a deficiency of ROCK1 results in increased macrophage and neutrophil migration in vitro.
21)
Next we investigated to determine how H1152 causes increases in EPC numbers and migration. Statins promote EPC differentiation, proliferation, migration, and cell survival in vitro by activating AKT signaling. 22, 23) Enhanced phosphorylation of AKT and GSK-3 has been found in ROCK1-deficient neutrophils. Day 5 EPCs were induced to migrate toward SDF-1 (10 ng/mL), VEGF (10 ng/mL), H1152 (0.01, 0.1, 1, 10 mM), or fasudil (1, 3, 10 mM) in the bottom chamber using a modified Boyden chamber. The migrating cells were stained using Diff-Quik solution, and were counted in four randomly selected fields. Values represent mean AE SE (n ¼ 4). Significant differences were evaluated by Tukey's test. ÃÃ p < 0:01; ÃÃÃ p < 0:001 compared with the no growth factor added control (noGF). Representative images of migrating cells are shown.
Enhancement of Endothelial Progenitor Cell Numbers and Migration
Hence we examined whether H1152 affects AKT signaling events in EPCs. After culture in EGM-2 containing 20% FBS for 4-5 d, EPCs were incubated for 30 min with the indicated inhibitor, followed by Western blot analysis, as described previously.
24) The antibody against phospho-AKT (Cell Signaling, Danvers, MA), p27 (Santa Cruz Biotechnology, Santa Cruz, CA), oractin (Sigma) was used. As shown in Fig. 3A , treatment with H1152 for 30 min increased the phosphorylation level of Akt, as compared to the untreated EPCs. Pretreatment with AKT inhibitor abolished EPC number increases due to H1152, whereas MEK1 inhibitor PD98059 had no effect (Fig. 3B) . Previously, atorvastatin increased EPC numbers by downregulation of cellcycle inhibitor p27. 25) Hence we compared the effect of H1152 on p27 expression with that of simvastatin. As shown in Fig. 3C, p27 was slightly reduced when treated with a high dose of H1152 for 24 h. Downregulation of p27 was also observed in the EPCs treated with fasudil and simvastatin. Simvastatin at 1 mM increased EPC numbers to 49% of the level of the fasudil effect. Thus the data suggest that ROCK inhibitor induces cell proliferation in part by downregulation of p27. However, ROCK inhibitor may exert its effect by a different pathway from statins, since statins exert their effects on EPCs independently of the ROCK pathway. 22, 25 ) ROCK inhibitor might enhance phosphorylation level of AKT in EPCs by modulating PTEN stability, as shown in ROCK1 deficiency of inflammatory cells. 21) Y27632 also reduces PTEN activity and enhances AKT activity in dissociated prostate epithelial cells. 26) Since EPCs show comparatively weak adhesion on matrix, AKT activation through PTEN modulation by ROCK inhibitor might occur in them, but it remains for further study to what extent such activity contributes to EPC proliferation, survival, and adhesion.
Increasing the number of circulating EPCs by transplantation of enriched hematopoietic stem cells or by injection of in vitro differentiated EPCs has been found to improve neovascularization of the ischemic hindlimb. 27, 28) Augmentation of EPC numbers by pharmacological modulation of the signaling pathways is a promising strategy for the treatment of ischemic disease, if the pharmacological modulator has additional beneficial effects. Our data indicate that H1152 increases the number of adherent spindle-shaped EPCs and enhances EPC migration without disrupting the actin cytoskeleton (H1152 ranging from 0.01 to 10 mM). ROCK inhibitors can also provide other benefits, such as inhibition of endothelial dysfunction. Hence we suggest that H1152 is valuable in the expansion of EPCs in therapeutic neovascularization.
